Igalphan Completes Acquisition of Fiducia Medical for Enhanced Development of IgA Antibody Drugs
Igalphan Completes Acquisition of Fiducia Medical
Igalphan Co., Ltd. has announced the complete acquisition of Fiducia Medical Co. (FM) through an exchange with its own stock options. This strategic move, finalized on June 30, 2026, aims to consolidate decision-making and optimize resource allocation for unified development both domestically and internationally.
Overview and Purpose of the Acquisition
The backdrop for this acquisition involves Igalphan's innovative efforts in developing oral immunoglobulin A (IgA) antibodies aimed at treating dysbiosis, a condition where the balance of gut microbiota is disrupted, leading to various health issues. This landmark acquisition not only facilitates a more cohesive growth strategy but also leads to the termination of a prior licensing agreement between Igalphan and FM. Going forward, Igalphan now holds exclusive global rights to these breakthrough therapies.
With this acquisition, Igalphan can significantly accelerate the development of critical technologies, including the establishment of large-scale production methods for IgA antibody-producing cell lines. Additionally, the company aims to strengthen pertinent functionalities and recruit talent necessary for a swift progression in its research and development efforts.
About Igalphan
Founded in April 2022, Igalphan's mission is to contribute to the Well-Being of both Earth and humanity through a healthy symbiosis between hosts, including humans, and gut microbiota. The company is on a mission to translate research breakthroughs led by Professor Reiko Nishizono at the University of Tokyo into practical applications. One of their pivotal developments is the rW27 pentameric IgA antibody, which targets and regulates gut microbiota.
Dysbiosis has been linked to a variety of significant diseases, including inflammatory bowel diseases, metabolic disorders, and even cancers. The rW27 IgA antibody does not kill harmful bacteria but suppresses their growth while promoting the proliferation of beneficial bacteria. This innovative approach has the potential to restore the balance of gut microbiota and mitigate health concerns associated with dysbiosis.
Igalphan holds a robust portfolio of over 10 global patents related to this antibody, including substance, manufacturing, and usage patents. Leveraging its proprietary manufacturing techniques will enable the high-efficiency production of IgA pentamer antibodies, positioning Igalphan at the forefront of therapeutics aimed at controlling and improving gut microbiota.
Message from Fiducia
Takuya Shibata, President of Fiducia, commented on this acquisition, stating that the integration of FM into Igalphan will rapidly enhance development in the field of IgA antibody pharmaceuticals. He emphasized the urgency of providing solutions to patients suffering from multiple diseases related to dysbiosis, underlining the importance of this acquisition in the broader healthcare landscape. The company aims to work closely with Igalphan's existing investors, focusing on the early development of the world’s first oral IgA antibody drugs.
Company Overview of Igalphan
- - Name: Igalphan Co., Ltd.
- - Representative: Takuji Shinkai, President
- - Location: 2-3-10 Mukogaoka, Bunkyo-ku, Tokyo, Japan, near the University of Tokyo HiRAKU GATE
- - Website: https://igalphan.jp
Contact for More Information
- - Email: [email protected]
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.